A Prospective, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly Vinorelbine as First Line Chemotherapy in Patients With Androgen Independent Prostate Cancer

Journal of Urology

Volumn 177, Issue 6, 2007, Pages 2141-2145

  Krainer, Michael ^a   Tomek, Sandra ^a   Elandt, Katarzyna ^a   Horak, Peter ^a   Albrecht, Walter ^b   Eisenmenger, Michael ^a   Höltl, Wolfgang ^c   Schramek, Paul ^d   Stackl, Walter ^b   Zielinski, Christoph ^a   Reibenwein, Jochen ^a  

^a Cancer Center   (Austria)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^c KAISER FRANZ JOSEF HOSPITAL   (Austria)

^d KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

Author keywords

docetaxel; drug therapy; prostatic neoplasms; vinorelbine

Indexed keywords

ANDROGEN; DOCETAXEL; NAVELBINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALGESIC ACTIVITY; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 34248161991     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.01.148     Document Type: Article

References (20)

1. Picus J., and Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26 (1999) 14
2. Friedland D., Cohen J., Miller Jr. R., Voloshin M., Gluckman R., Lembersky B., et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26 (1999) 19
3. Beer T.M., Pierce W.C., Lowe B.A., and Henner W.D. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12 (2001) 1273
4. Berry W., Dakhil S., Gregurich M.A., and Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28 (2001) 8
5. Gravis G., Bladou F., Salem N., Macquart-Moulin G., Serment G., Camerlo J., et al. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer 98 (2003) 1627
6. Ferrero J.M., Foa C., Thezenas S., Ronchin P., Peyrade F., Valenza B., et al. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology 66 (2004) 281
7. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502
8. Petrylak D.P., Tangen C.M., Hussain M.H., Lara Jr. P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513
9. Fields-Jones S., Koletsky A., Wilding G., O'Rourke M., O'Rourke T., Eckardt J., et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Ann Oncol 10 (1999) 1307
10. Oudard S., Caty A., Humblet Y., Beauduin M., Suc E., Piccart M., et al. Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol 12 (2001) 847
11. Morant R., Hsu Schmitz S.F., Bernhard J., Thurlimann B., Borner M., Wernli M., et al. Vinorelbine in androgen-independent metastatic prostatic carcinoma-a phase II study. Eur J Cancer 38 (2002) 1626
12. Robles C., Furst A.J., Sriratana P., Lai S., Chua L., Donnelly E., et al. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer. Oncol Rep 10 (2003) 885
13. Tralongo P., Bollina R., Aiello R., Di M.A., Moruzzi G., Beretta G., et al. Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A phase II study. Tumori 89 (2003) 26
14. Abratt R.P., Brune D., Dimopoulos M.A., Kliment J., Breza J., Selvaggi F.P., et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 15 (2004) 1613
15. Carles J., Domenech M., Gelabert-Mas A., Nogue M., Tabernero J.M., Arcusa A., et al. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncol 37 (1998) 187
16. Smith M.R., Kaufman D., Oh W., Guerin K., Seiden M., Makatsoris T., et al. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study. Cancer 89 (2000) 1824
17. Sweeney C.J., Monaco F.J., Jung S.H., Wasielewski M.J., Picus J., Ansari R.H., et al. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol 13 (2002) 435
18. Borrega P., Velasco A., Bolanos M., del Mar P.M., Mel J.R., Reina J.J., et al. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer. Urol Oncol 22 (2004) 32
19. Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756
20. Kantoff P.W., Halabi S., Conaway M., Picus J., Kirshner J., Hars V., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17 (1999) 2506